TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment

India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's TLC marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid in the country's emergency of acute liposomal amphotericin B shortage.
AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis, a serious fungal infection known as a black fungus.
With a high number of COVID-19 infections in India, the number of COVID-19 associated mucormycosis (CAM) cases has also been rising.
Yesterday, TLC's subsidiary InspirMed Inc presented data on the potential advantages of inhalable liposome formulations that can be used as prophylaxis and treatment for COVID-19.
Price Action: TLC shares are up 27.6% at $6.24 during the premarket session on the last check Tuesday.